The question now for Biogen is whether that difference is sufficiently compelling to encourage patients to switch from Tecfidera, or to start with Vumerity rather than one of its rival therapies.

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...

High-rolling investors have positioned themselves bullish on Biogen (NASDAQ:BIIB), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's ...

Also Read: Biogen Strengthens Pipeline With Stoke Therapeutic ... hospitals have also experienced negative effects from the switch. Approximately half of the NHS hospitals treating MS patients ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...